26250-87-3

Basic information

• Product Name: L-β-Homophenylalanine, HPLC 98%
• Synonyms: L-β-Homophenylalanine, HPLC 98%;(.BETA.S)-.BETA.-AMINO-BENZENEBUTANOIC ACID;(3S)-(+)-3-Amino-4-phenylbutyric acid;(S)-beta-Aminobenzenebutanoic acid;L-3-Amino-4-phenylbutyric acid;Benzenebutanoic acid, b-aMino-, (bS)-;(S)-b-Aminobenzenebutanoic acid
• CAS NO: 26250-87-3
• Molecular Formula: C₁₀H₁₃NO₂
• Molecular Weight: 179.21872
• Mol File: 26250-87-3.mol
• Article Data: 13

Chemical Properties

• Melting Point: 207℃
• Boiling Point: 324.8 °C at 760 mmHg
• Flash Point: 150.2 °C
• Appearance: /
• Density: 1.164
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 3.78±0.10(Predicted)
• CAS DataBase Reference: L-β-Homophenylalanine, HPLC 98%(CAS DataBase Reference)
• NIST Chemistry Reference: L-β-Homophenylalanine, HPLC 98%(26250-87-3)
• EPA Substance Registry System: L-β-Homophenylalanine, HPLC 98%(26250-87-3)

Safety Data

• Hazardous Substances Data: 26250-87-3(Hazardous Substances Data)

Usage

General Description

L-β-Homophenylalanine, HPLC 98% is a synthetic amino acid that is used in the production of pharmaceuticals and biochemical research. It is a derivative of phenylalanine and is commonly used in the development of new drugs, especially in the field of neuroscience. L-β-Homophenylalanine is highly pure, with a purity of 98% as determined by high-performance liquid chromatography (HPLC), making it suitable for use in sensitive research and production processes. Its high purity ensures minimal impurities and a consistent quality, which is crucial for its application in various pharmaceutical and biochemical studies.

Upstream product

• 777885-07-1 (+/-)-4-benzyl-2-azetidinone 
• 1039025-18-7 N-[(1S)-1-cyanomethyl-2-phenylethyl]-2,4,6-trimethylbenzenesulfonamide 
• 193954-28-8 (S)-3-(9H-fluoren-9-yl)methoxycarbonylamino-4-phenylbutanoic acid 
• 51871-62-6 (S)-3-tert-butoxycarbonylamino-4-phenylbutanoic acid 
• 211618-76-7 (S)-4-benzyl-2-azetidinone 
• 97206-05-8 methyl N-(benzyloxycarbonyl)-(3S)-3-amino-4-phenylbutanoate 
• 153708-33-9 (S)-6-benzyl-2-tert-butyl-1-methoxymethyl-3-methyl-2,3-dihydro-4(1H)-pyrimidinone 
• 100-52-7 benzaldehyde 
• 100-39-0 benzyl bromide 
• 41518-17-6 Z-Phe-O-COO-isoBu 
• 15196-02-8 (S)-3-[(benzyloxycarbonyl)amino]-1-diazo-4-phenyl-2-butanone 
• 1161-13-3 N-Cbz-L-Phe 
• 141403-49-8 (2S)-2-[N-(tert-butoxycarbonyl)amino]-3-phenyl-O-(4-methylphenylsulfonyl)propan-1-ol 
• 66605-57-0 (S)-N-tert-butoxycarbonyl-2-amino-3-phenylpropanol 

Downstream Products

• 26250-86-2 (S)-3-benzyloxycarbonylamino-4-phenylbutyric acid 
• 211619-48-6 4(S)-benzyl-3(S)-methoxyazetidin-2-one 
• 211618-78-9 (S)-4-Benzyl-1-(tert-butyl-dimethyl-silanyl)-azetidin-2-one 
• 211619-52-2 4(S)-benzyl-1-(tert-butyldimethylsilyl)-3(S)-hydroxyazetidin-2-one 
• 211619-30-6 (3S,4S)-3-Allyl-4-benzyl-1-(tert-butyl-dimethyl-silanyl)-azetidin-2-one 
• 211619-29-3 (3S,4S)-4-Benzyl-1-(tert-butyl-dimethyl-silanyl)-3-ethyl-azetidin-2-one 
• 211619-31-7 4(S)-benzyl-1-(tert-butyl-dimethylsilyl)-3(S)-methoxyazetidin-2-one 
• 211619-32-8 4(S)-benzyl-1-(tert-butyldimethylsilyl)-3(S)-(methylthio)azetidin-2-one 
• 211619-00-0 4(S)-Benzyl-2-oxoazetidine-1-carboxylic acid (4-pyridinylmethyl) amide 

Relevant articles and documents

METHOD FOR OBTAINING OPTICALLY PURE AMINO ACIDS

This invention relates to a method for obtaining optically pure amino acids, including optical resolution and optical conversion. This method significantly shortens the time taken for optical transformation, and enables the repeated use of an organic solution containing a enantioselective receptor, to thereby obtain optically pure amino acids in a simple and remarkably efficient manner, and to enable the very economical mass production of optically pure amino acids.

HETEROCYCLIC MODULATORS OF PKB

The invention relates to heterocyclic compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein Formula (I). The invention also relates to the therapeutic use of such compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

Synthesis of a β-tetrapeptide analog as a mother compound for the development of matrix metalloproteinase-2-imaging agents

Matrix metalloproteinase-2 (MMP-2) is an attractive target for the diagnosis of cancer and atherosclerosis in nuclear imaging. A cyclic decapeptide, cCTTHWGFTLC (cCTT), has been used as the mother compound for the development of MMP-2-imaging agents with high potency and selectivity. Most of radiolabeled derivatives of cCTT currently developed for in vivo studies of MMP-2, however, suffer from low accumulation in the target tissues, such as tumors. For enhanced in vivo stability and tissue penetration, we designed a linear β-tetrapeptide analog, H-β3-Phe-β-Ala- β3-Trp-β3-His-OH (1), to mimic cCTT. The component β-amino acids were prepared by reduction of N-protected α-amino acid methyl esters to the alcohols, followed by conversion into the cyanides, and subsequent hydrolysis. Compound 1 was obtained from these β-amino acids by the conventional solution method. In MMP-2 inhibition assay, compound 1 displayed desirably significant inhibition, which was comparable to cCTT. These findings suggest that compound 1 may serve as a mother compound in the design and development of in vivo MMP-2-imaging agents.